Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
19 Cards in this Set
- Front
- Back
|
Carbidopa-levodopa (Sinemet) works by a. blocking the action of acetylcholine. b. blocking the action of dopamine. c. increasing activation of dopamine recep-tors in the brain. d. increasing activation of acetylcholine re-ceptors in the brain. |
c
|
|
|
Carbidopa-levodopa (Sinemet) is preferred over plain levodopa in drug treatment of Parkinson disease because it a. is better absorbed from the GI tract. b. induces fewer CNS adverse effects. c. allows more dopamine to reach the brain. d. can be administered once a day. |
c
|
|
|
Which of the following adverse effects is not associated with the use of carbidopa-levodopa (Sinemet)? a. Thrombocytopenia b. Suicidal tendencies c. Ballismus d. Bruxism |
a
|
|
|
Drug interactions with carbidopa-levodopa (Sinemet) include a. most antibiotics. b. thiazide diuretics. c. hydantoins. d. cardiac glycosides. |
c
|
|
|
Centrally acting anticholinergic drugs are used in the management of Parkinson disease to a. inhibit the release of dopamine. b. increase the release of dopamine. c. inhibit the release of acetylcholine. d. increase the release of acetylcholine. |
c
|
|
|
Tolcapone (Tasmar) is used in the manage-ment of Parkinson disease to a. increase the amount of levodopa that reaches the brain. b. decrease the amount of levodopa that reaches the brain. c. block the conversion of levodopa to dopamine. d. increase the rate of conversion of levodopa to dopamine. |
a
|
|
|
Dopamine agonists such as pramipexole (Mirapex) and ropinirole (Requip) are used to a. block the adverse effects of carbidopa-levodopa. b. decrease the amount of carbidopa-levodo-pa needed to control the symptoms of Parkinson disease. c. block the action of acetylcholine in the periphery of the body. d. increase the conversion of levodopa to dopamine. |
b
|
|
|
A therapeutic indication for riluzole (Rilutek) is a. Parkinson disease b. multiple sclerosis. c. amyotrophic lateral sclerosis. d. Alzheimer disease. |
c
|
|
|
When given concurrently with riluzole (Rilutek), inhibitors of CYP1A 2, such as caf-feine or theophylline, may induce a. an increased risk for toxicity. b. subtherapeutic blood levels of riluzole. c. delayed absorption. d. increased elimination. |
a
|
|
|
Which of the following drugs would be inappropriate for use in the management of multiple sclerosis? a. Bromocriptine (Parlodel) b. Interferon beta c. Glatiramer acetate (Copaxone) d. Oxybutynin (Ditropan) |
a
|
|
|
You are assessing the patient’s health status for contraindications for carbidopa-levodopa therapy. Which of the following statements would you report to the provider? a. “My ophthalmologist says my glaucoma is getting worse.” b. “I have recurrent urinary tract infections.” c. “I’ve been taking amitriptyline (Elavil) for my depression.” d. “I haven’t had a migraine in 6 months.” |
a
|
|
|
Your patient is taking carbidopa-levodopa (Sinemet). In your assessment of lifestyle, diet, and habits, which of the following statements by the patient would you need to address? a. “I just love avocados! I could eat them every day.” b. “I tend to watch my meat intake because it bothers my stomach.” c. “I eat bran akes every morning.” d. “I drink at least 8 glasses of water a day.” |
a
|
|
|
Which of the following cultural groups may need dosing adjustments for symptom man-agement of Parkinson disease? a. Hispanic b. African American c. Chinese d. Caucasian |
c
|
|
|
Your patient has Parkinson disease and has been taking carbidopa-levodopa (Sinemet) for several years. Because of many adverse effects, the patient wishes to stop the drug. What should you tell this patient? a. “Drink lots of water in the next week to ush the drug out of your system.” b. “You really need to see the doctor before making that decision.” c. “Just decrease your dose to only once a day and see how you feel.” d. “That should be ne; I’ll make an ap-pointment for you to see the doctor next month.” |
b
|
|
|
Your patient is taking carbidopa-levodopa (Sinemet) and ropinirole (Requip) for Parkin-son disease. The patient asks, “Why do I need to take both of these drugs?” How would you respond? a. “Taking these drugs together decreases the potential for adverse effects.” b. “That is just the way this disease is treated.” c. “Why don’t you ask the doctor that question?” d. “Taking these drugs together stops the pro-gression of the disease.” |
a
|
|
|
Before the initiation of therapy with riluzole (Rilutek), the nurse should assess all of the fol-lowing laboratory data except a. renal function. b. complete blood count. c. arterial blood gases. d. hepatic function. |
c
|
|
|
Which of the following should be assessed related to the core patient variable of environ-ment for the patient taking riluzole therapy? a. The ability to climb stairs b. The ability to refrigerate the drug c. The ability to cover the cost of the drug d. The ability to store in a warm environment |
c
|
|
|
Your patient is prescribed riluzole (Rilutek) for ALS. Patient teaching should include a. “Don’t worry about your diet; you need all the calories you can get.” b. “Limit caffeine and high-fat foods.” c. “Decrease the amount of green leafy veg-etables.” d. “Be sure to drink at least 10 glasses of water a day.” |
b
|
|
|
Dalfampridine (Ampyra) is being administered to Jesse, a patient with multiple sclerosis to improve her ambulation. Patient education needs to include the two most serious adverse effects to monitor including a. hepatic and renal failure. b. sepsis and leukemia. c. cardiac dysrhythmias and dyspnea. d. seizures and hypersensitivity. |
d
|
